These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 35594766)

  • 1. A comprehensive review on potential therapeutic inhibitors of nosocomial Acinetobacter baumannii superbugs.
    Srikanth D; Joshi SV; Ghouse Shaik M; Pawar G; Bujji S; Kanchupalli V; Chopra S; Nanduri S
    Bioorg Chem; 2022 Jul; 124():105849. PubMed ID: 35594766
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multi-drug resistance of blood stream, urinary tract and surgical site nosocomial infections of Acinetobacter baumannii and Pseudomonas aeruginosa among patients hospitalized at Felegehiwot referral hospital, Northwest Ethiopia: a cross-sectional study.
    Motbainor H; Bereded F; Mulu W
    BMC Infect Dis; 2020 Jan; 20(1):92. PubMed ID: 32000693
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of Acinetobacter infections.
    Michalopoulos A; Falagas ME
    Expert Opin Pharmacother; 2010 Apr; 11(5):779-88. PubMed ID: 20210684
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Antibiotic resistance of Acinetobacter baumannii strains isolated from clinical specimens in the "Marius Nasta" Pneumology Institute, Bucharest].
    Moisoiu A; Ionită M; Sârbu L; Stoica C; Grigoriu L
    Pneumologia; 2014; 63(2):109-11. PubMed ID: 25241558
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emergence of antimicrobial resistance among Acinetobacter species: a global threat.
    Clark NM; Zhanel GG; Lynch JP
    Curr Opin Crit Care; 2016 Oct; 22(5):491-9. PubMed ID: 27552304
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of quorum sensing, biofilm formation, and iron acquisition as key virulence mechanisms in Acinetobacter baumannii and the corresponding anti-virulence strategies.
    Law SKK; Tan HS
    Microbiol Res; 2022 Jul; 260():127032. PubMed ID: 35483311
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Infections Due to Acinetobacter baumannii in the ICU: Treatment Options.
    Lynch JP; Zhanel GG; Clark NM
    Semin Respir Crit Care Med; 2017 Jun; 38(3):311-325. PubMed ID: 28578555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic options for Acinetobacter baumannii infections.
    Vila J; Pachón J
    Expert Opin Pharmacother; 2008 Mar; 9(4):587-99. PubMed ID: 18312160
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug treatment for multidrug-resistant Acinetobacter baumannii infections.
    Bassetti M; Righi E; Esposito S; Petrosillo N; Nicolini L
    Future Microbiol; 2008 Dec; 3(6):649-60. PubMed ID: 19072182
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antimicrobial resistance profiles and associated factors of Acinetobacter and Pseudomonas aeruginosa nosocomial infection among patients admitted at Dessie comprehensive specialized Hospital, North-East Ethiopia. A cross-sectional study.
    Mekonnen H; Seid A; Molla Fenta G; Gebrecherkos T
    PLoS One; 2021; 16(11):e0257272. PubMed ID: 34780494
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Dahdouh E; Hajjar M; Suarez M; Daoud Z
    Front Cell Infect Microbiol; 2016; 6():163. PubMed ID: 27933276
    [No Abstract]   [Full Text] [Related]  

  • 12. Developing new therapeutic approaches for treating infections caused by multi-drug resistant Acinetobacter baumannii: Acinetobacter baumannii therapeutics.
    Gallagher P; Baker S
    J Infect; 2020 Dec; 81(6):857-861. PubMed ID: 33115656
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification and characterization of novel isothiazolones with potent bactericidal activity against multi-drug resistant Acinetobacter baumannii clinical isolates.
    Luna BL; Garcia JA; Huang M; Ewing PJ; Valentine SC; Chu YM; Ye QZ; Xu HH
    Int J Antimicrob Agents; 2019 Apr; 53(4):474-482. PubMed ID: 30593847
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emergence of resistance to carbapenems in Acinetobacter baumannii in Europe: clinical impact and therapeutic options.
    Kempf M; Rolain JM
    Int J Antimicrob Agents; 2012 Feb; 39(2):105-14. PubMed ID: 22113193
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Confronting multidrug-resistant Acinetobacter baumannii: a review.
    Neonakis IK; Spandidos DA; Petinaki E
    Int J Antimicrob Agents; 2011 Feb; 37(2):102-9. PubMed ID: 21130607
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acinetobacter baumannii: an emerging multidrug-resistant threat.
    Gootz TD; Marra A
    Expert Rev Anti Infect Ther; 2008 Jun; 6(3):309-25. PubMed ID: 18588496
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extensively Drug-Resistant Acinetobacter baumannii Nosocomial Pneumonia Successfully Treated with a Novel Antibiotic Combination.
    Zaidan N; Hornak JP; Reynoso D
    Antimicrob Agents Chemother; 2021 Oct; 65(11):e0092421. PubMed ID: 34370576
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drugs with new lease of life as quorum sensing inhibitors: for combating MDR Acinetobacter baumannii infections.
    Seleem NM; Abd El Latif HK; Shaldam MA; El-Ganiny A
    Eur J Clin Microbiol Infect Dis; 2020 Sep; 39(9):1687-1702. PubMed ID: 32328851
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Carbapenem resistance in Acinetobacter baumannii, and their importance in hospital-acquired infections: a scientific review.
    Nguyen M; Joshi SG
    J Appl Microbiol; 2021 Dec; 131(6):2715-2738. PubMed ID: 33971055
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multidrug resistant Acinetobacter baumannii--the role of AdeABC (RND family) efflux pump in resistance to antibiotics.
    Wieczorek P; Sacha P; Hauschild T; Zórawski M; Krawczyk M; Tryniszewska E
    Folia Histochem Cytobiol; 2008; 46(3):257-67. PubMed ID: 19056528
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.